BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1560851)

  • 21. Multiple myeloma: a tailored therapy for elderly patients.
    Pileri A; Palumbo A; Boccadoro M
    Hematol Oncol; 1993; 11 Suppl 1():67-72. PubMed ID: 8486344
    [No Abstract]   [Full Text] [Related]  

  • 22. [Therapy of multiple myeloma: present and future].
    Tura S
    G Clin Med; 1986 Dec; 67(5-6):261-4, 266-7. PubMed ID: 3301488
    [No Abstract]   [Full Text] [Related]  

  • 23. [Allogeneic bone marrow transplantation in multiple myeloma].
    Bandini G; Rosti G; Cavo M; Albertazzi L; Rizzi S; Motta MR; Gobbi M; Tassi C; Tazzari PL; Miggiano C
    Haematologica; 1989 Oct; 74(5 Suppl):463-72. PubMed ID: 2512229
    [No Abstract]   [Full Text] [Related]  

  • 24. [Status and trends in hematology].
    Stobbe H
    Z Arztl Fortbild (Jena); 1986; 80(18):741-4. PubMed ID: 3544527
    [No Abstract]   [Full Text] [Related]  

  • 25. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
    McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multiple myeloma -- therapy].
    Jung W; Zettl F; Schroers R
    Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
    [No Abstract]   [Full Text] [Related]  

  • 27. Transplantation in multiple myeloma.
    Topolsky D; Biggs D
    Semin Oncol; 1995 Jun; 22(3):230-7. PubMed ID: 7777867
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of autologous stem cell transplantation in the management of multiple myeloma.
    Fermand JP; Brechignac S
    Pathol Biol (Paris); 1999 Feb; 47(2):199-202. PubMed ID: 10192889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
    Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
    Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Multiple myeloma].
    Almazov VA; Afanasév BV; Podoltseva ZI
    Klin Med (Mosk); 1993; 71(2):5-10. PubMed ID: 8046926
    [No Abstract]   [Full Text] [Related]  

  • 33. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy in multiple myeloma.
    Atkins CD
    N Engl J Med; 1996 Dec; 335(24):1844; author reply 1845. PubMed ID: 8965895
    [No Abstract]   [Full Text] [Related]  

  • 35. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].
    Shimokawa T; Kajiguchi T; Saito M; Kojima Y; Takeyama H
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):251-4. PubMed ID: 12610874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-intensified therapy combined with autologous blood stem cell support in patients with multiple myeloma.
    Serke S; Kirsch A; Huhn D
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):29-32. PubMed ID: 7528448
    [No Abstract]   [Full Text] [Related]  

  • 39. [Progress in the treatment of multiple myeloma].
    Wada M; Mizoguchi H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multiple myeloma: intensive chemotherapy and autotransplantation].
    Jubert-Leleu MC
    Soins; 1994 Oct; (589):34-6, 38. PubMed ID: 7676295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.